Status:
UNKNOWN
Stereotactic Radiotherapy Management of Brain Metastases: the Value of a Longitudinal Multimodal Approach (POSTPONE)
Lead Sponsor:
University Hospital, Brest
Conditions:
Brain Metastases, Adult
Eligibility:
All Genders
18+ years
Brief Summary
The management of brain metastases has evolved́ rapidly in recent years. It is estimated that 20% to 40% of cancer patients will develop brain metastases (BM) during the course of their disease. Whole...
Detailed Description
The management of brain metastases has evolved́ rapidly in recent years. It is estimated that 20% to 40% of cancer patients will develop brain metastases (BM) during the course of their disease. Whole...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Patients with solid cancer with brain metastases treated by hypofractionated external stereotactic radiotherapy at the CHRU de Brest between 01/01/2014 and 31/12/2022
- Patient affiliated to a social security scheme
Exclusion
- Patients with primary brain tumors
- Patients treated with normofractionated external cerebral radiotherapy
- Age \< 18 years
- Patients under legal protection (guardianship, curatorship, etc.)
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT06029140
Start Date
August 1 2023
End Date
September 1 2024
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Brest
Brest, France, 29609